Vaxart, Inc. To Present Preclinical Data On Oral Quadrivalent Influenza Vaccine At ICAAC/ICC 2015

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Vaxart Associate Director of Research Ciaran Scallan, PhD, will present preclinical study data at the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego, California.

Help employers find you! Check out all the jobs and post your resume.

Back to news